Q-omics provides the consensus-scored VARS1 profile across patient tissues and cancer cell-line models. VARS1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, VARS1 is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, VARS1 RNA expression shows 18,822 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, COAD, and ACC as cancer lineages where VARS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VARS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VARS1 survival associations across molecular data types. VARS1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VARS1 RNA expression–survival associations across cancer types. High VARS1 expression shows unfavorable associations in MESO, COAD, LIHC, ACC, SKCM and LAML. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for VARS1 RNA expression.
This table summarizes VARS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for VARS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VARS1 shows higher tumor expression in COAD, KIRC, KIRP, STAD, BLCA and THCA. The COAD box plot shows higher VARS1 RNA expression in tumor versus normal tissue (log2 FC = +1.565, t-test p < 0.001).
This table shows molecular features associated with VARS1 in patient tissues and cancer cell lines. In patient samples, VARS1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, VARS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
